A small clinical trial published in Psychological Medicine on June 15, 2026, found that prucalopride, a medication approved to treat chronic constipation, improved performance on tests of memory, attention, and processing speed in adults with a history of depression after approximately one week of treatment. The study, led by Dr. Angharad de Cates from the University of Birmingham and colleagues at the University of Oxford, offers the first randomized evidence that this class of drug may specifically address cognitive symptoms that persist in patients with depression even after their mood has recovered.
The drug, sold under the brand name Resolor in the United Kingdom and Motegrity in the United States, is already on pharmacy shelves for its approved constipation indication. The finding that it also produces measurable improvement in post-depression cognitive function after only a short course of treatment is driving significant interest in whether it could be formally evaluated and eventually approved for a new psychiatric indication.
Why This Matters
Depression is commonly understood as a disorder of mood, but it is also a disorder of cognition. Difficulties with thinking, planning, memory, attention, and processing speed are standard features of active depressive episodes. What is less commonly recognized is that these cognitive deficits often persist after a patient's mood has improved, a phenomenon clinicians call residual cognitive impairment or colloquially describe as brain fog. For many people in remission from depression, this persistent cognitive dysfunction is one of the most disabling aspects of the illness, affecting their ability to work, maintain relationships, and fully resume their lives.
No drug is currently approved specifically for post-depression cognitive impairment. Existing antidepressants address mood and sometimes improve cognition indirectly, but they are not designed or proven to target the cognitive symptoms directly. Prucalopride works through a different receptor than any existing antidepressant, raising the possibility of a genuinely new treatment pathway for this unmet need.
What We Know So Far
The trial enrolled 50 adults who had previously experienced depressive episodes but had been in remission for at least six months and were not taking psychiatric medication at the time of enrollment. Participants were randomly assigned to receive either 2 mg of prucalopride daily, the same dose approved for constipation, or a placebo, for between 7 and 10 days. Before and after the treatment period, participants completed a battery of cognitive tests designed to measure executive function, short-term memory, long-term memory, and emotional cognition.
Participants who received prucalopride showed faster and more accurate performance across the cognitive test battery compared to those who received placebo, according to the University of Birmingham press release and EurekAlert. The improvements were seen across both objective measures of "cold" cognitive function, such as working memory and processing speed, and tests of emotional cognition. No significant side effects were reported in the prucalopride group.
The drug works by stimulating a specific serotonin receptor called the 5-HT4 receptor, which is found in both the gut and the brain. Prior research had suggested that the 5-HT4 receptor plays a role in memory and learning, and earlier studies in healthy volunteers had shown cognitive improvements with prucalopride. This trial is the first randomized evidence that those effects also appear in people with a history of depression.
Where the Impact Is Highest
Depression affects an estimated 21 million American adults annually, and the subset who experience residual cognitive symptoms after remission is substantial. Adults in middle-working-age years, roughly 30 to 55, are most likely to be affected by post-depression brain fog in ways that directly impair occupational functioning, and are also most likely to seek treatment for it. Major academic medical centers with psychiatry and neuroscience programs, including those affiliated with the NIHR Oxford Health Biomedical Research Centre where this trial was supported, are the most likely venues for the larger trials that would need to follow.
What Doctors and Experts Say
"Cognitive problems, or brain fog, are an important and often overlooked feature of depression, and can persist even when mood improves," said Dr. Angharad de Cates, lead author and NIHR clinical lecturer at the University of Birmingham. "Our study suggests that a targeted serotonin 5-HT4 receptor medication, already used for chronic constipation, may improve cognitive functioning in people with a history of depression."
De Cates was also candid about the trial's limitations and the next steps required. In comments to Newsweek, she said: "Our findings offer promise for addressing cognitive problems in depression, but this research area is still at the exploratory phase. We need dedicated clinical trials in this area before it can become a treatment option." She emphasized that despite the drug's availability for constipation, people should not use it as a treatment for cognitive symptoms without medical supervision.
Medscape's commentary on the study included an independent assessment noting that the study population was predominantly female, white, highly educated, and younger than 40, limiting the generalizability of the findings. The independent expert also raised a question about whether the cognitive improvements reflected correction of baseline impairment or general cognitive enhancement, since cognitive deficits were not among the inclusion criteria for the trial.
What the Evidence Shows and What It Does Not
This is a small double-blind, placebo-controlled, randomized proof-of-concept trial published in peer-reviewed Psychological Medicine on June 15, 2026 (DOI: 10.1017/S0033291726104450), led by the University of Birmingham and University of Oxford, enrolling 50 adults with remitted major depressive disorder.
The study found that prucalopride produced faster and more accurate cognitive test performance compared to placebo across multiple cognitive domains after 7 to 10 days of treatment, with no significant adverse effects reported.
What the study did not prove is that the effect generalizes to diverse populations, that it represents treatment of actual cognitive impairment rather than enhancement in unimpaired participants, or that it produces durable benefits beyond the 7 to 10-day treatment window. The trial was underpowered for some cognitive tasks due to missing data, and the study population's demographics limit how broadly the findings can be applied. This is a proof-of-concept study requiring replication in larger, more diverse populations with confirmed baseline cognitive impairment before any prescribing guidance can change. Readers should know that prucalopride is not approved for cognitive symptoms and should not be used for this purpose without physician guidance.
Who Faces the Greatest Risk Without a Cognitive Treatment Option
People in remission from major depressive disorder who continue to experience significant memory problems, poor concentration, difficulty with planning and executive tasks, and persistent mental slowness despite mood improvement have no currently approved treatment specifically targeting these symptoms. This group may have difficulty returning to work, maintaining relationships, and regaining full quality of life after depression, making the unmet need clinically significant and economically important.
Symptoms and Warning Signs to Watch For
Post-depression cognitive symptoms typically include word-finding difficulties, slower information processing, difficulty concentrating on extended tasks, poor short-term memory for new information, and trouble organizing or planning multi-step activities. These symptoms may be subtle enough that patients minimize them or attribute them to aging, even when they represent a significant decline from pre-depression function. Discussing these specific symptoms with a prescribing physician or psychiatrist during follow-up appointments is important, as they may affect treatment planning and monitoring.
Anyone experiencing a return of depressive mood symptoms alongside cognitive difficulties should seek prompt clinical evaluation, as a relapse of depression rather than residual cognitive impairment may be occurring.
What You Can Do Now
People managing residual cognitive symptoms after depression should discuss them explicitly with their psychiatrist or primary care physician. Documenting specific examples of cognitive difficulty, when they occur, how they affect daily functioning, and how they compare to function before the depressive episode helps clinicians assess the severity and trajectory. Cognitive behavioral therapy has evidence for improving cognitive dysfunction in depression, and structured exercise programs have also shown benefit for post-depression cognition through mechanisms including increased neuroplasticity and reduced inflammation.
Patients interested in being evaluated for potential clinical trials testing prucalopride or other 5-HT4 receptor agonists for depression-related cognition can search ClinicalTrials.gov.
Cost and Access: What Patients Should Know
Prucalopride (Motegrity) is available in the United States by prescription for its approved constipation indication, with costs typically ranging from $300 to $500 per month without insurance. It is covered by many insurance plans for the approved indication. It is not covered or approved for cognitive symptoms, meaning any off-label use would not be covered by insurance. The research team has explicitly cautioned against off-label use for cognitive symptoms before larger clinical trials validate the finding.
Community mental health centers and academic psychiatry programs offer cognitive evaluation and behavioral interventions for post-depression cognitive symptoms at a range of costs.
What Happens Next
Dr. de Cates and colleagues have announced plans to continue investigating treatments for cognitive difficulties associated with major depressive disorder. A larger trial specifically enrolling patients with confirmed baseline cognitive impairment and a more diverse demographic profile would be the logical next step toward any regulatory application. Previous research on 5-HT4 receptor agonists has also raised the possibility that this class of drug may help reduce the risk of depression relapse, expanding the potential application beyond cognition. MedicalDaily will report on follow-up trial designs and results as they are announced.
The Bottom Line
A one-week course of an already-approved constipation medication produced measurable improvements in memory, attention, and thinking speed in a small group of adults with a history of depression. The brain fog that persists after depression affects millions of people and has no currently approved treatment. This proof-of-concept finding does not change prescribing practice today, but it opens a specific and testable therapeutic avenue toward addressing one of depression's most functionally debilitating features. Patients experiencing residual cognitive symptoms should raise them with their physician as a legitimate clinical problem, not an expected side effect of recovery.
